Rectal Cancer Stage I
Conditions
Keywords
Preoperative chemoradiotherapy, Transanal endoscopic microsurgery, Rectal Cancer, T1-N0-M0 Rectal cancer
Brief summary
Introduction: The standard treatment for rectal adenocarcinoma is total mesorectal excision (TME), a technique involving resection of the rectum, with or without a temporary or permanent stoma. TME is associated with high morbidity and genitourinary alterations. On the other hand, transanal endoscopic surgery (TEM) allows access to tumors up to 20 cm from the anal margin, with much lower postoperative morbidity and without the need for ostomy. For T1, N0, M0 rectal adenocarcinomas without poor prognostic factors, TEM is the technique of choice. However, recent studies have described local recurrences of up to 20%. Our group, TAUTEM, has just completed a phase III clinical trial in T2-T3ab, N0, M0 rectal cancer, comparing preoperative chemoradiotherapy (CRT) and TEM versus TME, with very positive results in terms of postoperative morbidity, quality of life, and a local recurrence rate of 7.4%, not inferior to TME. These results encourage our TAUTEM group to launch a similar project at the T1, N0, M0 stage, comparing standard TEM treatment versus QRT and TEM, aiming to improve rectal preservation outcomes and enhance results regarding local recurrence, distant recurrence, and oncologic survival. Method: Prospective, controlled, randomized phase III multicenter clinical trial. Patients with rectal adenocarcinoma within 10 cm of the anal margin and up to 4 cm in size, staged as T1, N0, M0, will be included. These patients will be randomized into two groups: TEM after CRT and TEM alone. Postoperative morbidity and mortality, CRT side effects, and quality of life will be recorded. The minimum follow-up will evaluate rectal preservation and local recurrence and survival at two and three years. The sample size calculation for the study will be 106 patients. Conclusions: The aim of the study is to improve oncological outcomes in stage T1, N0, M0 rectal cancer through preoperative chemoradiotherapy associated with local surgery (TEM).
Interventions
Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
RADIATION50.4 Gy
Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
10 weeks after Chemoradiotherapy
PROCEDURETransanal Endoscopic Microsurgery
Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
Sponsors
Corporacion Parc Tauli
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Indication by multidisciplinary committee of indication for local excision, according to ESMO and NCCN criteria. * Rectal adenocarcinomas in the biopsy, located at a distance from the anal margin less than or equal to 10 cm measured by rigid rectoscopy at the time of ER. * Preoperative staging by ER and pelvic MRI of T1,N0. In case of disparity, higher staging will be considered the definitive diagnosis. If it is greater than T1, it will be excluded. * Tumors equal to or less than 4 cm in maximum diameter measured by MRI. * ASA index equal to or less than III. * Absence of distant metastases by abdominal CT and chest X-ray (if inconclusive, Thoracic CT)
Exclusion criteria
* Preoperative staging by EER or pelvic MRI higher than T1 or N0. * Presence of distant metastases. Synchrony with other colorectal adenocarcinomas. * Undifferentiated rectal adenocarcinomas or with the presence of poor prognostic factors in the preoperative biopsy (undifferentiated, venous, lymphatic or perineural infiltration, budding) . * Patients with intolerance to preoperative chemotherapy or radiotherapy. * Do not sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rectal preservation in T1,N0,M0 rectal cancer | 2 years | Number of patients where local surgery has been maintained after applying the protocol exit criteria.minimum follow-up of 2 years in both groups. |
| Total mesorectal excision in T1,N0,M0 rectal cancer | 2 years | Number of patients with Total mesorectal Excision (TME) after applying the protocol exit criteria.minimum follow-up of 2 years in both groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The clinical and pathological response of patients undergoing CRT. | 30 days after surgery | The presence of a correct histological response after chemoradiotherapy is determined by the pathology study of the tumor excised after TEM, in order to establish TRG1 in Bouzourene's classification |
| Quality of life one year after surgery. | One year after surgery | Law anterior resection syndrom (LARS), Wexner incontinence scale, EORTC QLQ-C30, EORTC QLQ-CR29, and Karnofsky quality of life questionnaires. Before treatment and One year after surgery en both groups |
| Analysis of tolerance and side effects of preoperative chemoradiotherapy (CRT). | 30 days after preoperative CRT | NCI Common Terminology Criteria for Adverse Events v3.0 after chemoradiotherapy, is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. |
| 3-year survival results in both groups, | Three years | 3-year survival results in both groups, reflected in overall survival, disease-free survival (DFS), distant recurrence (DR), and rectal cancer survival. |
| Local recurrence in both groups | At two years | Local recurrence defined as the presence of adenocarcinoma in the biopsy on the residual scar, anastomosis, or the defect area of the excised tumor. |
| Postoperative morbidity and mortality in both groups. | 30 days after surgery | Postoperative (30 days post-surgery): nosocomial, surgical, and non-surgical postoperative complications; complications according to the Dindo-Clavien classification and the CCI (Comprehensive Complication Index); hospital stay. |
Contacts
Primary ContactXavier Serra-Aracil, MD
Outcome results
None listed